Physician profile
John Neily
NPI 1760553630
$3,998.73
in general payments reported to CMS, 2019-2025
24 companies · $428 in 2025
The $428 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $496 · 2021: $385 · 2022: $618 · 2023: $515 · 2024: $809 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.67 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $453.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $375.33 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $346.22 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $341.13 | 2019-2024 | Adbry |
| Amgen INC. | $269.30 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $255.96 | 2019-2024 | Blu-U, Ilumya |
| Genentech USA, INC. | $212.46 | 2019-2024 | Xolair |
| Genzyme Corporation | $195.44 | 2019-2024 | |
| Lilly USA, LLC | $187.68 | 2019-2024 | Taltz |
| Pfizer INC. | $161.28 | 2019-2023 | |
| Incyte Corporation | $62.56 | 2022-2025 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $50.18 | 2023-2024 | Valchlor |
| Galderma Laboratories, L.P. | $44.48 | 2022-2025 | Nemluvio |
| Organogenesis INC. | $44.14 | 2020-2023 | Puraply |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $40.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.87 | 2024 | Sotyktu |
| Merz North America, INC. | $37.40 | 2022 | |
| Strata Skin Sciences, INC. | $31.67 | 2020-2022 | |
| Ucb, INC. | $29.47 | 2023 | Bimzelx |
| Kyowa Kirin, INC. | $24.85 | 2024 | Poteligeo |
| Dermavant Sciences, INC. | $22.44 | 2022 | |
| Biofrontera INC. | $22.01 | 2025 | Ameluz |
| Almirall LLC | $19.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Neily listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.